Forbes contributors provide expert insights on drug pricing policies. The Trump Administration's most favored nation (MFN) policy to control drug prices may not solve U.S. healthcare issues. Addressing market inefficiencies and PBMs' excessive revenues are crucial for reducing costs and improving access.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing